Clinical Trial Update: Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence [NA]

View source ↗

Summary

This clinical trial evaluated whether adalimumab serum levels influence prevention of postoperative recurrence in Crohn's disease and has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Crohn Disease | NA | Status: TERMINATED